Browse the evidence

There is a greater emphasis on adjunct pharmacotherapy in the updated guideline, particularly with GLP-1-based agents for weight reduction and improvement of comorbidities.

Healthcare providers should integrate GLP-1-based pharmacotherapy into obesity management strategies.

Binge eating episodes and prevalence reduced following liraglutide and semaglutide.

Practitioners may find liraglutide and semaglutide effective in reducing binge eating behaviors in patients.

PAP+tirzepatide was associated with lower incident PH at 1 year (RR:0.27) and 3 years (RR:0.22), and lower mortality at 1 year (RR:0.14) and 3 years (RR:0.12).

Using tirzepatide in conjunction with PAP may provide superior benefits in reducing PH and mortality for obese patients with OSA.

Compared to PAP+semaglutide, PAP+tirzepatide showed lower incident PH at 1 year (RR:0.51) and 3 years (RR:0.42) and lower all-cause mortality at 1 year (RR:0.41) and 3 years (RR:0.33).

Tirzepatide may offer enhanced benefits over semaglutide for reducing PH and mortality in obese patients with OSA on PAP.

Blood pressure control, ACE inhibitor therapy, and statins have proven benefits in reducing cardiovascular risk in Type 2 diabetes.

Healthcare providers should implement these treatments to mitigate cardiovascular risks.

The GLP-1 receptor agonist Semaglutide and the GIPR/GLP-1R co-agonist Tirzepatide lead to a weight loss greater than 10%.

Practitioners can consider Semaglutide and Tirzepatide as effective options for weight management in patients with obesity and Type 2 diabetes.

GLP-1 agonists such as liraglutide and semaglutide are more efficacious than other approved drugs in weight management therapy.

Practitioners may consider GLP-1 agonists as a preferred option for weight management in diabetic patients.

Tirzepatide reduces fasting and postprandial glucose levels, food consumption, and body weight in people with type 2 diabetes.

Tirzepatide may be an effective treatment option for managing blood glucose and weight in type 2 diabetes patients.

Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight.

Practitioners may consider GLP-1 agonists and incretin multi-agonists as effective options for weight management in obese patients.

GLP-1 based medications can achieve an average weight loss of 24%.

Practitioners can expect significant weight loss with GLP-1 medications.

GLP-1-agonists significantly reduce the risk of cardiovascular endpoints in patients with overweight or obesity without diabetes, with a Number Needed to Treat (NNT) of 44.

GLP-1-agonists may be considered for reducing cardiovascular risk in non-diabetic patients with obesity.

Incretin drug therapy can produce significant weight loss in properly selected individuals.

Clinicians should consider incretin therapy for weight loss in appropriately selected patients.

Bariatric surgery is the most effective treatment for obesity, yielding sustainable weight loss of about 20-30%.

Bariatric surgery should be considered for patients with obesity seeking significant weight loss.

GLP-1 receptor agonist semaglutide 2.4 mg and dual GLP-1 and GIP agonist tirzepatide have raised the bar for weight loss efficacy in obesity pharmacotherapies.

Clinicians should consider GLP-1 and GIP agonists as effective options for obesity treatment.

Combinations of GLP-1 RA, GIP, and glucagon RA (retatrutide) have shown weight loss efficacy approaching that of bariatric surgery.

Combination therapies may offer significant weight loss benefits similar to surgical options.

Second-generation drugs for obesity treatment can achieve weight loss of 15-25%, comparable to bariatric surgery.

Healthcare professionals can consider second-generation drugs as effective options for weight management in obese patients.

GLP-1 receptor agonists can achieve weight loss of 15-17% with a good safety profile.

GLP-1 receptor agonists are a viable treatment option for weight loss in obese patients.

Tirzepatide can achieve weight loss of up to 22.5% at the highest doses.

Tirzepatide represents a potent option for significant weight loss in obese patients.

Once-weekly GLP-1RA therapy can produce substantial weight loss over prolonged treatment (up to 23% at 72 weeks), alongside improvements in metabolic outcomes and reduced cardiometabolic risk.

GLP-1RA therapies can be effective for significant weight loss and improving metabolic health in obese patients.

Inkretin-basierte Medikamente (GLP-1- und GIP/GLP-1-Rezeptoragonisten) und SGLT-2-Inhibitoren (SGLT2i) ermöglichen eine bislang nicht erreichte Gewichtsreduktion und reduzieren nachweislich kardiovaskuläre Ereignisse (MACE).

Practitioners should consider these medications as effective options for weight management and cardiovascular risk reduction.

Die Kombination von GLP-1-Rezeptoragonisten und SGLT2i zeigt additive Vorteile und wird leitliniengerecht bei Typ-2-Diabetes mit hohem Risiko empfohlen.

Healthcare providers should consider this combination therapy for high-risk type 2 diabetes patients.

Advanced pharmacotherapy with GLP-1 receptor agonists can achieve 15%–20% weight loss.

Clinicians can consider GLP-1 receptor agonists as an effective pharmacotherapy option for weight loss.

Recent antiobesity drugs have shown weight loss effects of 12%–17% and can resolve NASH in some patients.

Consider the use of antiobesity medications as part of a comprehensive treatment plan for NASH.

Tirzepatide has demonstrated superior efficacy in promoting weight loss and maintaining a healthy body weight compared to traditional incretin therapies.

Tirzepatide may be a more effective option for weight management in patients with obesity.